Department of Molecular and Cellular Biochemistry, Ohio State University, Columbus, OH; Molecular, Cellular and Developmental Biology Program, Ohio State University, Columbus, OH.
Hepatology. 2014 Feb;59(2):555-66. doi: 10.1002/hep.26712. Epub 2013 Dec 20.
c-Myc is a well-known oncogene frequently up-regulated in different malignancies, whereas liver-specific microRNA (miR)-122, a bona fide tumor suppressor, is down-regulated in hepatocellular cancer (HCC). Here we explored the underlying mechanism of reciprocal regulation of these two genes. Real-time reverse-transcription polymerase chain reaction (RT-PCR) and northern blot analysis demonstrated reduced expression of the primary, precursor, and mature miR-122 in c-MYC-induced HCCs compared to the benign livers, indicating transcriptional suppression of miR-122 upon MYC overexpression. Indeed, chromatin immunoprecipitation (ChIP) assay showed significantly reduced association of RNA polymerase II and histone H3K9Ac, markers of active chromatin, with the miR-122 promoter in tumors relative to the c-MYC-uninduced livers, indicating transcriptional repression of miR-122 in c-MYC-overexpressing tumors. The ChIP assay also demonstrated a significant increase in c-Myc association with the miR-122 promoter region that harbors a conserved noncanonical c-Myc binding site in tumors compared to the livers. Ectopic expression and knockdown studies showed that c-Myc indeed suppresses expression of primary and mature miR-122 in hepatic cells. Additionally, Hnf-3β, a liver enriched transcription factor that activates miR-122 gene, was suppressed in c-MYC-induced tumors. Notably, miR-122 also repressed c-Myc transcription by targeting transcriptional activator E2f1 and coactivator Tfdp2, as evident from ectopic expression and knockdown studies and luciferase reporter assays in mouse and human hepatic cells.
c-Myc represses miR-122 gene expression by associating with its promoter and by down-regulating Hnf-3β expression, whereas miR-122 indirectly inhibits c-Myc transcription by targeting Tfdp2 and E2f1. In essence, these results suggest a double-negative feedback loop between a tumor suppressor (miR-122) and an oncogene (c-Myc).
c-Myc 是一种众所周知的癌基因,在不同的恶性肿瘤中经常上调,而肝特异性 microRNA(miR)-122 是一种真正的肿瘤抑制因子,在肝细胞癌(HCC)中下调。在这里,我们探讨了这两个基因相互调节的潜在机制。实时逆转录聚合酶链反应(RT-PCR)和 northern blot 分析表明,与良性肝脏相比,c-MYC 诱导的 HCC 中初级、前体和成熟 miR-122 的表达降低,表明 MYC 过表达时 miR-122 的转录抑制。事实上,染色质免疫沉淀(ChIP)试验显示,与 c-MYC 未诱导的肝脏相比,肿瘤中 RNA 聚合酶 II 和组蛋白 H3K9Ac 的结合显著减少,这是活性染色质的标志物,表明 miR-122 在 c-MYC 过表达肿瘤中的转录抑制。ChIP 试验还表明,与肝脏相比,c-Myc 与 miR-122 启动子区域的结合显著增加,该区域含有一个保守的非典型 c-Myc 结合位点。异位表达和敲低研究表明,c-Myc 确实抑制了肝细